A complex U.S. Supreme Court drug-labeling decision that was issued this week gave both sides partial victories and has touched off a furious last-minute dispute in a similar drug case involving the suicide of a Reed Smith partner that the justices are set to consider Thursday.

Supplemental briefs in Dolin v. GlaxoSmithKline were filed on Wednesday, with the drug company telling the court that part of the May 20 decision in Merck Sharp & Dohme Corp. v. Albrecht was “irrelevant.” The plaintiff’s lawyer countered with a brief asserting that GlaxoSmithKline was “mistaken” and that the Dolin case should be granted review or sent back to an appeals court for review in light of the justices’ Merck decision.